Sintx Technologies, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Sintx Technologies, Inc. has filed its 2023 10-K annual report, detailing its financial performance and business operations.</b>

AI Summary

Sintx Technologies, Inc. (SINT) filed a Annual Report (10-K) with the SEC on March 27, 2024. Sintx Technologies, Inc. filed its annual report for the fiscal year ended December 31, 2023. The company's SIC code is 3841 for Surgical & Medical Instruments & Apparatus. The filing covers the period from January 1, 2023, to December 31, 2023. Key dates include the filing date of March 27, 2024, and the fiscal year end of December 31, 2023. The report details financial information for the fiscal years 2023, 2022, and 2021.

Why It Matters

For investors and stakeholders tracking Sintx Technologies, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Sintx Technologies' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial data and risk factors outlined in the report are essential for stakeholders to understand the company's market position, potential challenges, and investment risks.

Risk Assessment

Risk Level: medium — Sintx Technologies, Inc. shows moderate risk based on this filing. The company's financial performance and operational status are detailed in this 10-K filing, which is a standard requirement for public companies. However, without specific financial results or forward-looking statements within this header data, a definitive risk assessment is limited.

Analyst Insight

Review the full 10-K filing to analyze Sintx Technologies' financial statements, revenue streams, and management's discussion and analysis to understand its current financial health and future growth potential.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-27 — Filing Date (As of date)
• 2023 — Fiscal Year (Reporting period)
• 2022 — Previous Fiscal Year (Comparative data period)
• 2021 — Prior Fiscal Year (Comparative data period)

Key Players & Entities

• Sintx Technologies, Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• 2024-03-27 (date) — Filing date
• 3841 (other) — Standard Industrial Classification

FAQ

Industry Context

Sintx Technologies operates in the Surgical & Medical Instruments & Apparatus industry (SIC 3841). This sector involves the manufacturing and distribution of medical devices and equipment.

Regulatory Implications

As a publicly traded company, Sintx Technologies is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual reports on Form 10-K.

What Investors Should Do

1. Thoroughly review the financial statements and Management's Discussion and Analysis (MD&A) section of the 10-K for detailed insights into revenue, expenses, and profitability.
2. Examine the risk factors section to understand potential challenges and uncertainties facing Sintx Technologies.
3. Analyze any disclosed executive compensation and corporate governance information to assess management's alignment with shareholder interests.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-03-27: Filing Date — Date Sintx Technologies, Inc. submitted its 10-K report.

Year-Over-Year Comparison

This filing is the 2023 Form 10-K, providing the annual overview of Sintx Technologies' financial and operational status, superseding previous quarterly and annual reports.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value SINT The NASDAQ Capital M

Filing Documents

• form10-k.htm (10-K) — 1946KB
• ex4-23.htm (EX-4.23) — 22KB
• ex21-1.htm (EX-21.1) — 2KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32.htm (EX-32) — 5KB
• ex97.htm (EX-97.1) — 41KB
• 0001493152-24-011546.txt (&nbsp;) — 7354KB
• sint-20231231.xsd (EX-101.SCH) — 47KB
• sint-20231231_cal.xml (EX-101.CAL) — 84KB
• sint-20231231_def.xml (EX-101.DEF) — 212KB
• sint-20231231_lab.xml (EX-101.LAB) — 490KB
• sint-20231231_pre.xml (EX-101.PRE) — 367KB
• form10-k_htm.xml (XML) — 870KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 22 Item 1B. Unresolved Staff Comments 42 Item 1C. Cybersecurity 42 Item 2.

Properties

Properties 42 Item 3.

Legal Proceedings

Legal Proceedings 42 Item 4. Mine Safety Disclosures 42 PART II 43 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43 Item 6. Reserved 43 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 43 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 54 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 54 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 54 Item 9A.

Controls and Procedures

Controls and Procedures 54 Item 9B. Other Information 55 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 55 PART III 56 Item 10. Directors, Executive Officers and Corporate Governance 56 Item 11.

Executive Compensation

Executive Compensation 62 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 67 Item 13. Certain Relationships and Related Transactions, and Director Independence 68 Item 14. Principal Accountant Fees and Services 69 PART IV 70 Item 15. Exhibits and Financial Statement Schedules 70 Item 16. Form 10-K Summary 75

Signatures

Signatures 76 Index to Consolidated Financial Statements F-1 2 CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are forward-looking to identify forward-looking statements by using words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and similar words. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly and annual results, our ability to manage our growth, our ability to achieve and sustain profitability, demand for our products, our ability to compete successfully, our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changes and applicable laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, and general economic conditions, and other risks set forth throughout this Annual Report, including under "Item 1, Business," "Item 1A, Risk Factors," and "Item 7, Management's Discussion

BUSINESS

BUSINESS Overview – SINTX Technologies SINTX Technologies is an advanced ceramics company formed in December 1996, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. We have grown from focusing primarily on the research, development and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical and antipathogenic applications. This diversification enables us to focus on our core competencies which are the manufacturing, research, and development of products comprised from advanced ceramic materials for external partners. We seek to connect with new customers, partners and manufacturers to help them realize the goal of leveraging our expertise in advanced ceramics to create new, innovative products across these sectors. SINTX Core Business Biomedical Applications: Since its inception, SINTX has been focused on medical grade silicon nitride. SINTX biomedical products have been shown to be biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 in the US, Europe, Brazil, and Taiwan. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Bacterial infection of any biomaterial implants is always a concern. SINTX silicon nitride has been shown to be resistant to bacterial colonization and biofilm formation, making it antibacterial. SINTX silicon nitride products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements. We believe that silicon nitride has a superb combination of properties that make it suited for long-term human i

View Full Filing

View this 10-K filing on SEC EDGAR